Nevertheless, he added, there remains “a bit of mystery” regarding the mechanism of benefit, as there was no significant reduction in sudden cardiac death or presumed arrhythmic death in the n-3 PUFA group. And the optimal dosage has yet to be defined, Dr. Komajda said.
GISSI-HF was simultaneously published online (Lancet 2008 Aug. 31 [doi:10.1016/50140–6736(08)61239–8]).
The trial was funded by the Società Prodotti Antibiotici S.p.A., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., and AstraZeneca Pharmaceuticals, which provided Dr. Tavazzi with research support and honoraria.
There was a significant adjusted 9% relative risk reduction in the n-3 PUFA group. DR. TAVAZZI